Error loading player: No playable sources found

Player size: small large

Targeting PI3K-gamma with IPI-549, a Tumor Macrophage-Reprogramming Small Molecule, in Patients with Advanced Solid Tumors

Date

September 23, 2020

Speaker

Brenda C. O'Connell, PhD

Infinity Pharmaceuticals, Inc

Tracks

Targeting Myeloid Cells in Cancer Therapy II

Related Products

Thumbnail for Short Talk: Antagonistic Antibodies Targeting LAIR1 Promote Inflammatory Phenotypes in Myeloid Cells and Activate Lymphocytes

Short Talk: Antagonistic Antibodies Targeting LAIR1 Promote Inflammatory Phenotypes in Myeloid Cells and Activate Lymphocytes

Thumbnail for Short Talk: Elevated Systemic Myeloid-Derived Suppressor Cells and Interleukin 8 Correlate with Increased Incidence of Venous Thromboembolism in Cancer Patients Receiving Immune-Checkpoint Inhibitors

Short Talk: Elevated Systemic Myeloid-Derived Suppressor Cells and Interleukin 8 Correlate with Increased Incidence of Venous Thromboembolism in Cancer Patients Receiving Immune-Checkpoint Inhibitors

Thumbnail for Short Talk: Extracellular Vesicles Derived from a Commensal Bacteria Enhance Anticancer Immunity by Modulating Tumor Infiltrating Immune Cells

Short Talk: Extracellular Vesicles Derived from a Commensal Bacteria Enhance Anticancer Immunity by Modulating Tumor Infiltrating Immune Cells

Thumbnail for Arming Tumor-Associated Macrophages to Reverse Epithelial Cancer Progression

Arming Tumor-Associated Macrophages to Reverse Epithelial Cancer Progression

Privacy Policy Update: We value your privacy and want you to understand how your information is being used. To make sure you have current and accurate information about this sites privacy practices please visit the privacy center by clicking here.